loader
Please Wait
Applying Filters...

Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Technical details about Rucaparib, learn more about the structure, uses, toxicity, action, side effects and more

    Client Email Product
    Menu

    Rucaparib

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    2D Structure
    1. Also known as: 1859053-21-6, Rucaparib (camsylate), Rucaparib (monocamsylate), Pf-1367338-bw, C0-338, [(1s,4r)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
    Molecular Formula
    C29H34FN3O5S
    Molecular Weight
    555.7  g/mol
    InChI Key
    INBJJAFXHQQSRW-STOWLHSFSA-N
    FDA UNII
    41AX9SJ8KO
    Rucaparib Camsylate is the camsylate salt form of rucaparib, an orally bioavailable tricyclic indole and inhibitor of poly(ADP-ribose) polymerases (PARPs) 1 (PARP1), 2 (PARP2) and 3 (PARP3), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, rucaparib selectively binds to PARP1, 2 and 3 and inhibits PARP-mediated DNA repair. This enhances the accumulation of DNA strand breaks, promotes genomic instability and induces cell cycle arrest and apoptosis. This may enhance the cytotoxicity of DNA-damaging agents and reverse tumor cell resistance to chemotherapy and radiation therapy. PARPs are enzymes activated by single-strand DNA breaks that catalyze the post-translational ADP-ribosylation of nuclear proteins, which induces signaling and the recruitment of other proteins to repair damaged DNA. The PARP-mediated repair pathway plays a key role in DNA repair and is dysregulated in a variety of cancer cell types.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1S,4R)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one
    2.1.2 InChI
    InChI=1S/C19H18FN3O.C10H16O4S/c1-21-10-11-2-4-12(5-3-11)18-14-6-7-22-19(24)15-8-13(20)9-16(23-18)17(14)15;1-9(2)7-3-4-10(9,8(11)5-7)6-15(12,13)14/h2-5,8-9,21,23H,6-7,10H2,1H3,(H,22,24);7H,3-6H2,1-2H3,(H,12,13,14)/t;7-,10-/m.1/s1
    2.1.3 InChI Key
    INBJJAFXHQQSRW-STOWLHSFSA-N
    2.1.4 Canonical SMILES
    CC1(C2CCC1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
    2.1.5 Isomeric SMILES
    CC1([C@@H]2CC[C@]1(C(=O)C2)CS(=O)(=O)O)C.CNCC1=CC=C(C=C1)C2=C3CCNC(=O)C4=C3C(=CC(=C4)F)N2
    2.2 Other Identifiers
    2.2.1 UNII
    41AX9SJ8KO
    2.3 Synonyms
    2.3.1 Depositor-Supplied Synonyms

    1. 1859053-21-6

    2. Rucaparib (camsylate)

    3. Rucaparib (monocamsylate)

    4. Pf-1367338-bw

    5. C0-338

    6. [(1s,4r)-7,7-dimethyl-2-oxo-1-bicyclo[2.2.1]heptanyl]methanesulfonic Acid;6-fluoro-2-[4-(methylaminomethyl)phenyl]-3,10-diazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-9-one

    7. Co-338

    8. 41ax9sj8ko

    9. Rucaparib Camsylate [usan]

    10. Bicyclo(2.2.1)heptane-1-methanesulfonic Acid, 7,7-dimethyl-2-oxo-, (1s,4r)-, Compd. With 8-fluoro-1,3,4,5-tetrahydro-2-(4-((methylamino)methyl)phenyl)-6h-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (1:1)

    11. Bicyclo[2.2.1]heptane-1-methanesulfonic Acid, 7,7-dimethyl-2-oxo-, (1s,4r)-, Compd. With 8-fluoro-1,3,4,5-tetrahydro-2-[4-[(methylamino)methyl]phenyl]-6h-pyrrolo[4,3,2-ef][2]benzazepin-6-one (1:1)

    12. Rucaparib(camsylate)

    13. Ag14699 Camsylate

    14. Rucaparib Camphosulfonate

    15. Rucaparib Camphorsulfonate

    16. Chembl3833368

    17. Rucaparib Camsylate [mi]

    18. Schembl22817574

    19. Amy9250

    20. Chebi:134692

    21. Dtxsid301027866

    22. 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6h-pyrrolo(4,3,2-ef)(2)benzazepin-6-one (7,7-dimethyl-2-oxobicyclo(2.2.1)heptan-1-yl)methanesulfonate (1:1)

    23. Bcp18101

    24. Ex-a3053

    25. Rucaparib Camsylate [who-dd]

    26. S5195

    27. Cs-6939

    28. Rucaparib Camsylate [orange Book]

    29. Ac-30110

    30. Hy-102003

    31. A902311

    32. Q27258428

    33. ((1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic Acid - 8-fluoro-2-(4-((methylamino)methyl)phenyl)-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one (1:1)

    34. [4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1h-azepino[5,4,3-cd]indol-2-yl)phenyl]-n-methylmethanaminium [(1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl]methanesulfonate

    35. 8-fluoro-5-(4-((methylamino)methyl)phenyl)-2,3,4,6-tetrahydro-1h-azepino[5,4,3-cd]indol-1-one ((1s,4r)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate

    2.3.2 Other Synonyms

    1. 283173-50-2

    2. Rubraca

    3. Rucaparib

    4. 8237f3u7eh

    2.4 Create Date
    2016-08-16
    3 Chemical and Physical Properties
    Molecular Weight 555.7 g/mol
    Molecular Formula C29H34FN3O5S
    Hydrogen Bond Donor Count4
    Hydrogen Bond Acceptor Count7
    Rotatable Bond Count5
    Exact Mass555.22032053 g/mol
    Monoisotopic Mass555.22032053 g/mol
    Topological Polar Surface Area137 Ų
    Heavy Atom Count39
    Formal Charge0
    Complexity869
    Isotope Atom Count0
    Defined Atom Stereocenter Count2
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameRUBRACA
    Active IngredientRUCAPARIB CAMSYLATE
    CompanyCLOVIS ONCOLOGY INC (Application Number: N209115. Patents: 6495541, 7351701, 7531530, 8071579, 8143241, 8754072, 8859562, 9045487, 9861638)

    4.2 Drug Indication

    Treatment of fallopian tube cancer , Treatment of ovarian cancer , Treatment of primary peritoneal cancer , Treatment of prostate malignant neoplasms

    Post Enquiry
    POST ENQUIRY